MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Dopamine modulates learning conflicting action-valence associations in Parkinson’s disease

N.C. van Wouwe, D.O. Claassen, J.S. Neimat, S.A. Wylie (Nashville, TN, USA)

Meeting: 2016 International Congress

Abstract Number: 1412

Keywords: Cognitive dysfunction, Executive functions

Session Information

Date: Wednesday, June 22, 2016

Session Title: Parkinson's disease: Cognition

Session Time: 12:00pm-1:30pm

Location: Exhibit Hall located in Hall B, Level 2

Objective: To investigate the effect of dopaminergic medication in Parkinson’s disease (PD) on learning to act and learning to withhold action based on rewarding versus punishing outcomes.

Background: There is an extensive literature on the role of dopamine in reward-based learning. Disorders associated with altered dopamine function in the Basal Ganglia, such as Parkinson’s disease, have been shown to disrupt this learning. Although the role of dopamine in learning to act has been investigated extensively, the role of dopamine in learning to withhold (or inhibit) action to influence outcomes is not as well understood.

Methods: We studied 19 Parkinson’s disease patients ‘On’ and ‘Off’ medication versus 30 healthy older adults on a probabilistic action-valence learning task. During this task subjects learned to act or withhold action to obtain reward or to avoid a punishment. Outcome valence and action were orthogonolized by this paradigm (action-reward, inaction-reward, action-punishment, inaction-punishment) and participants learned each of the four action-valence combinations.

Results: All participants demonstrated inherent learning biases preferring action with reward and inaction to avoid punishment and this was unaffected by dopamine in Parkinson’s disease. However, dopamine modulated the ability to learn less natural action-valence associations (withholding action to obtain a reward and acting to avoid punishment). ‘Off’ dopamine medication, patients demonstrated impairments in learning to withhold action to gain reward, whereas ‘On’ dopamine medication, patients showed a reduced ability to learn to act to avoid punishment.

Conclusions: The current findings suggest that dopamine in Parkinson’s disease is most critical when learning requires overriding natural action-valence tendencies in favor of less natural associations between action and valence. This paradigm could be useful to investigate learning biases in other basal ganglia disorders such as Huntington’s disease or Tourette’s disease and could provide insight into maladaptive action or valence biases in impulse control disorder. The findings might also have implications for rehabilitation learning and the motivators used in different medication states and with different movement disorders.

A similar abstract will be presented at CNS, NY, April 2016.

To cite this abstract in AMA style:

N.C. van Wouwe, D.O. Claassen, J.S. Neimat, S.A. Wylie. Dopamine modulates learning conflicting action-valence associations in Parkinson’s disease [abstract]. Mov Disord. 2016; 31 (suppl 2). https://www.mdsabstracts.org/abstract/dopamine-modulates-learning-conflicting-action-valence-associations-in-parkinsons-disease/. Accessed June 14, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/dopamine-modulates-learning-conflicting-action-valence-associations-in-parkinsons-disease/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Humor processing is affected by Parkinson’s disease and levodopa
      • Help & Support
      • About Us
      • Cookies & Privacy
      • Wiley Job Network
      • Terms & Conditions
      • Advertisers & Agents
      Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
      Wiley